Benicar - Injuries & Lawsuits

This week, Tokyo-based pharmaceutical firm Daiichi-Sankyo Ltd. announced that it will pay out $300 million to settle approximately 2,300 cases filed by plaintiffs who allege that its olmesartan blood pressure medications were responsible for their intestinal injuries. This comes two years after the company paid $39 million to the...

Last week, the Hon. Judge Robert Kugler denied a motion by Benicar plaintiffs for partial summary judgment against drugmaker Daiichi-Sankyo on the matter of causation. Lawyers for the plaintiffs argued that testimony from Daiichi, in addition from information gleaned from company emails during the discovery process, constituted an admission...

Plaintiffs who have filed legal action against Benicar maker Daiichi Sankyo will not be able to compel testimony from company employees who work in the company's European operation. That ruling came down from U.S. District Magistrate Judge Joel Schneider for the District of New Jersey at the end of...

Currently, drugmaker Daiichi-Sankyo is facing in excess of 1700 lawsuits over the hypertension prescription drug Benicar, which has been linked to sprue-like enteropathy. The link to this condition, which mimics the symptoms of celiac disease or gluten intolerance, was discovered by a physician at the Mayo Clinic in 2012....

One thing can be said for Daiichi Sankyo. It is very forthcoming about the side effects of its controversial blood pressure medication, Benicar – at least, all but one. If one visits the product's home page at benicar.com, one will see a nearly complete laundry list of possible side...

Japanese pharmaceutical company Daiichi-Sankyo was recently the recipient of a dubious honor: its flagship product was selected as one of three prescription drugs with the most dangerous side effects. That prescription is Benicar (olmesartan medomoxil), the blood pressure medication that has been associated with sprue-like enteropathy, a condition that mimics...

Lawsuits over the hypertension medication Benicar (over 1,100 as of the beginning of October) allege that executives at Daiichi-Sankyo were aware of the product’s dangerous side effects and withheld that information from the public. In light of this allegation, those injured by the drug are wondering why it took...

Lawsuits against Benicar manufacturer Daiichi-Sankyo will finally go to trial late next year, according to a U.S. District judge in New Jersey. The first trials are scheduled to begin in the fall of 2016.Currently, the number of lawsuits over the blood pressure medication exceeds 1,100. However, those in the...

Daiichi Sankyo, the drugmaker of the popular blood pressure medication Benicar (olmesartan medoxomil), is facing scrutiny as several individuals have filed Benicar lawsuits, alleging the drug caused them to develop a severe and chronic gastrointestinal condition known as sprue-like enteropathy.The Levin, Papantonio law firm is currently investigating cases where...

4The prescription drug Benicar (olmesartan medoxomil) has been linked to a severe form of a gastrointestinal condition known as spruelike enteropathy. The drug is commonly prescribed to treat high blood pressure, or hypertension.Symptoms of spruelike enteropathy include chronic diarrhea and substantial weight loss. In July, the FDA issued a...